Evidence map›Paper›PMID 34630099›Full record

ArticleFrontiers in pharmacology2021

Berberine Potentiates Insulin Secretion and Prevents β-cell Dysfunction Through the miR-204/SIRT1 Signaling Pathway.

Xiaoyan Lv, Yali Zhao, Xuehan Yang, Hao Han, Yue Ge, Meishuang Zhang, Hansi Zhang, Ming Zhang, Li Chen

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Berberine: A Negentropic Modulator for Multi-System Coordination.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xiaoyan LvDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Yali ZhaoDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Xuehan YangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Hao HanDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Yue GeDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Meishuang ZhangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Hansi ZhangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Ming ZhangDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.
Li ChenDepartment of Pharmacology, College of Basic Medical Sciences, Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic β-cell dysfunction is a key link during the progression of type 2 diabetes (T2DM), and SIRT1 participates in the regulation of various physiological activities of islet β-cells. However, as a key link in signal transduction, it is not clear how SIRT1 is regulated. By TargetScan prediction, we found that miR-204, which is enriched in islets, has highly complementary binding sites with SIRT1. Therefore, we speculate that miR-204 may be the upstream regulatory target of SIRT1 in islets and thus participate in the occurrence of β-cell dysfunction. In this study, we explored the association between miR-204 and β-cell dysfunction, the therapeutic effects of berberine (BBR) on β-cell function and the possible mechanisms. We found that miR-204 increased and SIRT1 mRNA and protein levels decreased significantly in islets both

Indexed as

apoptosisberberinemiR-204SIRT1type 2 diabetesβ-cell dysfunction

Identifiers

PMID34630099
PMCPMC8493072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.